New insider activity at BridgeBio Pharma ( (BBIO) ) has taken place on August 11, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BridgeBio Pharma’s Chief Accounting Officer, Maricel Apuli, recently executed a transaction involving the sale of 1,000 shares of the company’s stock. This sale amounted to a total value of $45,440.
Recent Updates on BBIO stock
In the last 24 hours, BridgeBio Pharma’s stock has seen significant developments, primarily driven by its recent Q2 earnings report and analyst reactions. The company reported substantial revenue growth, largely due to the successful launch of its product, Attruby, which generated $71.5 million in net product revenue. This performance exceeded some estimates but fell short of others, leading to a 12% post-market decline in share prices. Analysts from Scotiabank and Oppenheimer raised their price targets for BridgeBio, citing the company’s early commercial success and the accelerated launch trajectory of Attruby. Meanwhile, Raymond James adjusted its price target slightly downward, reflecting the stock’s year-to-date outperformance and strong early demand metrics. Despite the mixed reactions, analysts remain optimistic about BridgeBio’s potential for future growth, driven by its strategic focus on genetic diseases and promising clinical pipeline advancements.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
BridgeBio Pharma’s overall stock score is driven by strong revenue growth and positive earnings call sentiment, highlighting successful product launches and pipeline progress. However, significant challenges in profitability, financial stability, and valuation weigh down the score.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
YTD Price Performance: 65.18%
Average Trading Volume: 2,998,201
Technical Sentiment Signal: Buy
Current Market Cap: $8.9B